NCT03501459View on ClinicalTrials.gov

Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome

PHASE3RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2025

Conditions

Nephrotic Syndrome

Interventions

DRUG

Rituximab

Trial Locations (1)

Unknown

RECRUITING

National University Hospital, Singapore

All Listed Sponsors

lead

National University Health System, Singapore

OTHER